Monitoring for Tardive Dyskinesia: Who Is at Greatest Risk?

By Brianna Graham, Mar 12, 2025

The Abnormal Involuntary Movement Scale (AIMS) is the gold standard for monitoring TD symptoms. It is recommended to screen patients at the start of antipsychotic treatment, annually for most patients, and every six months for high-risk groups, including older adults and those on FGAs. In addition, Alex Dimitriu, MD, advises clinicians to “regularly review medications for TD potential by checking for dopamine-blocking agents.”

Click HERE for the full article.